

Putting Patients First

Lumiio believes we need to -- and can -- do better for patients. With people at the core of all they do, Lumiio is transforming the rare disease community by empowering patients through real-world evidence (RWE) to unlock the future of personalized patient outcomes.

MitoCanada is one of the rare disease organizations Lumiio is working with. Lumiio developed the recently-launched MitoCanada Patient Contact Registry to help unite our mitochondrial disease community and gather data to solve some of the daunting challenges that mito patients, and their caregivers, face.

This collaboration will help reach its goal of ensuring all lives are powered by healthy mitochondria while Lumiio hopes it will propel them forward to help thousands more. There are over 7,000 rare diseases and therapies for only 5% of them.

Lumiio uses its platform to unite passion, data and technology to solve our biggest health challenges. They incorporate emerging technology, like wearables, to integrate all patient data to track biomarkers and eventually algorithms to predict and inform real-time care and health outcomes.

The benefits of this technology are plentiful and powerful. For example, if we predict a health crisis before it happens by proactively monitoring an individual's biomarkers, we can influence decisions that may keep them alive and change the trajectory of their life. Another example is access to valuable, real-time data. Having this information can lead to an earlier, more accurate diagnosis while helping to advance the development of safe, effective and affordable therapies for patients.

We asked Lumiio why they chose to Sponsor and Ride at the 2022 MitoSpin. They answered that in addition to wanting to support the MitoCommunity, they know our MitoMotivators are inspiring and that the event is empowering.



With a clear understanding of the power of community, Lumiio is much more than a technology company. The Lumiio team is intimately aware of the patient journey as most have lived experience with rare disease.

This includes CEO, Blaine Penny, who is also the co-founder of MitoCanada. Blaine's son Evan is severely disabled by mitochondrial disease. At the 2021 MitoSpin, Blaine rode for 762 minutes (yes, that's well over 12 hours!) cycling over 400 kms. He says people living with mito face extreme fatigue and major health challenges due to energy deficits caused by their disease, every day. He's more than willing to share his energy with them to support MitoCanada.

This year, with his Lumiio teammates supporting him, Blaine intends to ride 1 km for every \$10 he raises. This will likely secure another 12+ hours of cycling on February 26th. Blaine welcomes the opportunity to push himself to the limit. With determination like that, some people say Blaine is a machine. Those who know him better assert that he is an extraordinary man who loves his son and wants to ensure Evan, and others living with mitochondrial disease, enjoy the best quality of life possible.



You can meet and support the Lumiio team at: Lumiio